Increasing unusual put option volume: UNIT REN TSM LSI ALNY SSRM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alnylam Pharmaceuticals (ALNY) PT Raised to $134 at BMO Capital; Makes Case for $165 Upside Scenario
September 21, 2017 3:40 PM EDTBMO Capital analyst Do Kim raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $134.00 (from $99.00) while maintaining an Outperform rating following strong APOLLO data.
"We believe an early restart of Fitusiran trials and positive Givosiran interim data (mid-2018) would enable shares to approach our $165 upside scenario," the analyst said.
... MoreAlnylam Pharmaceuticals (ALNY) PT Raised to $101 at Morgan Stanley
September 21, 2017 8:37 AM EDTMorgan Stanley raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $101.00 (from $50.00) while maintaining a Equalweight rating.
... MoreUPDATE: Alnylam Pharmaceuticals (ALNY) PT Raised to $146 at Ladenburg Thalmann
September 21, 2017 7:04 AM EDT(Updated - September 21, 2017 7:08 AM EDT)
(updated to add analyst comment)
Ladenburg Thalmann analyst Christopher James raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $146.00 (from $90.00) while maintaining a Buy rating.
The analyst is positive on the results from... More
